Abstract
Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have